Letrazole
CAS 112809-51-5
Letrazole Description:
Femara is a third generation aromatase inhibitor. Like most aromatase inhibitors it was developed to fight breast cancer by inhibiting aromatization via the aromatase enzyme. It is similar to arimidex, however femara is much more potent in it's ability and is used primarily when other treatments such as selective estrogen receptor modulators have failed to produce results. This is why the majority of the research about femara has been conducted on post-menopausal women, but of course some of the findings can be translated over for the benefit of athletes.
Letrazole Use/Dosing:
Anecdotally users have reported seeing good results using doses ranging from about .25mgs per day to .5mgs per day. However these doses do vary quite widely from user to user, including dosing schedules. Some have reported using the compound every other day or every third day with good results. Also, doses reported have ranged from .25mgs to as much as 2.5mgs per day.
Despite this anecdotal evidence it should be noted that doses as low as 100 micrograms can cause the maximum inhibition of the aromatase enzyme. It is therefore advisable that users experiment with their dosages to find what levels can be maintained for the compound to be fully effective, while minimizing side effects. Of course if a user is trying to treat side effects that have already appeared one may want to err on the side of using too much femara and face those side effects rather than dealing with something like gynocomastia. However, the severity of the condition will likely determine this in most cases.
The maximum dosage that a user would want to use would be 2.5mgs per day. It has been shown in numerous studies that this dosage will eliminate nearly all of the estrogen in the body in nearly all individuals. Any dose that is higher than this would simply be unneeded.
Despite the ability to increase the amount of lutenizing hormone, follicle stimulating hormone, and sex hormone binding globulin in users femara can be counterproductive if used during post-cycle therapy. This is due to the ability of the compound to drive estrogen levels too low during use. Once the compound is discontinued this can result in a "rebound effect" in estrogen levels with these becoming quite high, something that should be avoided during or after post-cycle therapy. Anastrozole could be seen as an alternative to femara in this capacity as it seemingly does not have such a potent effect. The detrimental effect that femara has on blood lipid levels is another reason why many will avoid it's use during post-cycle therapy, and this is discussed below.
About the dosing, you need to make a choice in combination with your body condition, or consult your trainer / doctor. This article is for reference only.
China (Mainland)